Home > Press Releases > Anti-Migraine Drugs Market

Anti-Migraine Drugs Market Likely to Surpass USD 10.4 Billion by 2035

Report Code: HC-11438  |  Published in: Jun 2026, By MarketGenics  |  Number of pages: 367
Get PDF
Buy

Global Anti-Migraine Drugs Market Forecast 2035:

According to the report, the global Anti-Migraine Drugs market is projected to expand from USD 4.3 billion in 2025 to USD 10.4 billion by 2035, registering a CAGR of 9.2%, the highest during the forecast period. The growing global burden of migraine and headache disorders, increasing diagnosis rates, and increasing recognition of migraine as a significant neurological disorder affecting quality of life and productivity are driving the Anti-Migraine Drugs market. Educating patients and health care professionals is helping to increase awareness and improve the uptake of migraine-specific treatments.

Treatment outcomes continue to improve and the transition from traditional preventive medications to more specific treatments, such as CGRP-targeted therapies (monoclonal antibodies and gepants), continues to grow. Further drivers of uptake of the advanced migraine therapies in key health markets include regulatory approvals, positive clinical data, and growing reimbursement coverage.

Novel mechanisms like PACAP-targeting therapeutics, bispecific antibodies, and advanced oral formulations are being heavily developed and funded by pharmaceutical companies to meet unmet clinical needs. Growth in the market is also driven by a growing demand for treatments that can be self-administered, greater access to treatments for children, and higher healthcare spending on neurological disorders. Acute and preventive migraine treatment is continuously evolving and improving worldwide.

The global anti-migraine drugs market is growing at a sustainable rate as new therapies are being developed and introduced in the market, patient access is increasing and innovative strategies are being adopted.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Anti-Migraine Drugs Market”

The focus of care has shifted towards more preventive treatment of migraines to help decrease the frequency of attacks, healthcare utilization, and overall burden of the disease. As physicians and patients increasingly embrace preventive treatments, the trend is driving up the adoption of more sophisticated anti-migraine therapies, especially those prescribed for those who suffer from frequent or disabling migraine headaches.

Despite therapeutic advancements, long-term adherence to migraine treatment remains a challenge due to side effects, variable patient response, treatment fatigue, and switching between therapies. These can make people less likely to adhere to treatment and make the overall effectiveness of migraine management programs less effective.

The expansion of healthcare infrastructure, growing neurological disease awareness and the growing spread of insurance coverage in emerging economies are creating a lot of opportunities for anti-migraine drug manufacturers. Increased access to specialist care and innovative treatments is driving companies to access different patient populations that were previously not being reached and significantly increasing their international presence.

Regional Analysis of Global Anti-Migraine Drugs Market

  • The anti-migraine drugs market is expected to experience a high demand from North America as preventive migraine therapies gain popularity, neurologists are well established and new drugs are quickly incorporated into clinical practice. This is due to the high level of investment in healthcare, high-level diagnostic skills and good access to treatment for patients suffering from chronic and episodic migraine in the region.
  • Improving healthcare infrastructure and increasing neurological disease awareness, as well as the escalating diagnosis of migraine disorders across Asia Pacific, are driving the fastest growth in the anti-migraine drugs market. Increased health care spending, more comprehensive insurance, and more effective therapies are promoting more patients to get medical care.
  • The anti-migraine drugs market is witnessing substantial growth in Europe, as a result of rising adoption of targeted drugs for migraine, supportive regulatory environment and a high focus on preventive neurological care. Treatment uptake is gaining momentum due to higher awareness among healthcare providers, growing acceptance of innovative treatments by reimbursers and the robust clinical research efforts.

Key players in the global anti-migraine drugs market include AbbVie Inc., Amgen Inc. (Aimovig), Cafergot (Advanz Pharma), Eli Lilly and Company, GlaxoSmithKline plc, Grünenthal Group (Zomig), H. Lundbeck A/S (Vyepti), Novartis AG, Pfizer Inc. (Nurtec ODT), Teva Pharmaceutical Industries Ltd. (AJOVY), Other Key Players.

The global anti-migraine drugs market has been segmented as follows:

Global Anti-Migraine Drugs Market Analysis, By Drug Class

  • Triptans
  • Gepants (CGRP Receptor Antagonists)
  • Ditans (5-HT1F Receptor Agonists)
  • Ergot Alkaloids
  • Antidepressants (Prophylactic)
  • Anti-CGRP Monoclonal Antibodies
  • NSAIDs & Analgesics
  • Combination Drugs

Global Anti-Migraine Drugs Market Analysis, By Treatment Type

  • Abortive Treatment
  • Prophylactic Treatment
  • Rescue Therapy

Global Anti-Migraine Drugs Market Analysis, By Migraine Type

  • Migraine with Aura
  • Migraine without Aura
  • Chronic Migraine
  • Episodic Migraine
  • Hemiplegic Migraine
  • Vestibular Migraine
  • Hormonal Migraine
  • Others (Retinal Migraine, etc.)

Global Anti-Migraine Drugs Market Analysis, By Route of Administration

  • Oral
  • Injectable
  • Intranasal
  • Transdermal

Global Anti-Migraine Drugs Market Analysis, By Drug Type

  • Innovator Drugs
  • Generic Drugs
  • Biosimilars

Global Anti-Migraine Drugs Market Analysis, By Patient Demographics

  • Pediatric (< 12 years)
  • Adolescent (12–17 years)
  • Adult (18–64 years)
  • Geriatric (≥ 65 years)

Global Anti-Migraine Drugs Market Analysis, By End-users

  • Hospital & Inpatient Care
  • Specialty Neurology & Headache Clinics
  • Pain Management Clinics
  • Ambulatory & Outpatient IV Infusion Centers
  • Others

Global Anti-Migraine Drugs Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

​​​About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Anti-Migraine Drugs Market Outlook
      • 2.1.1. Anti-Migraine Drugs Market Size Value (US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising Global Prevalence of Migraine and Chronic Headache Disorders
        • 4.1.1.2. Increasing Adoption of Novel CGRP-Targeted Migraine Therapies
        • 4.1.1.3. Growing Awareness, Diagnosis Rates, and Access to Neurological Care
      • 4.1.2. Restraints
        • 4.1.2.1. High Cost of Advanced Biologic and Specialty Migraine Treatments
        • 4.1.2.2. Side Effects and Limited Treatment Response in Some Patient Populations
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Anti-Migraine Drugs Market Demand
      • 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size - Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Anti-Migraine Drugs Market Analysis, by Drug Class
    • 6.1. Key Segment Analysis
    • 6.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Drug Class, 2021-2035
      • 6.2.1. Triptans
      • 6.2.2. Gepants (CGRP Receptor Antagonists)
      • 6.2.3. Ditans (5-HT1F Receptor Agonists)
      • 6.2.4. Ergot Alkaloids
      • 6.2.5. Antidepressants (Prophylactic)
      • 6.2.6. Anti-CGRP Monoclonal Antibodies
      • 6.2.7. NSAIDs & Analgesics
      • 6.2.8. Combination Drugs
  • 7. Global Anti-Migraine Drugs Market Analysis, by Treatment Type
    • 7.1. Key Segment Analysis
    • 7.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Treatment Type, 2021-2035
      • 7.2.1. Abortive Treatment
      • 7.2.2. Prophylactic Treatment
      • 7.2.3. Rescue Therapy
  • 8. Global Anti-Migraine Drugs Market Analysis, by Migraine Type
    • 8.1. Key Segment Analysis
    • 8.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Migraine Type, 2021-2035
      • 8.2.1. Migraine with Aura
      • 8.2.2. Migraine without Aura
      • 8.2.3. Chronic Migraine
      • 8.2.4. Episodic Migraine
      • 8.2.5. Hemiplegic Migraine
      • 8.2.6. Vestibular Migraine
      • 8.2.7. Hormonal Migraine
      • 8.2.8. Others (Retinal Migraine, etc.)
  • 9. Global Anti-Migraine Drugs Market Analysis, by Route of Administration
    • 9.1. Key Segment Analysis
    • 9.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 9.2.1. Oral
      • 9.2.2. Injectable
      • 9.2.3. Intranasal
      • 9.2.4. Transdermal
  • 10. Global Anti-Migraine Drugs Market Analysis, by Drug Type
    • 10.1. Key Segment Analysis
    • 10.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Drug Type, 2021-2035
      • 10.2.1. Innovator Drugs
      • 10.2.2. Generic Drugs
      • 10.2.3. Biosimilars
  • 11. Global Anti-Migraine Drugs Market Analysis, by Patient Demographics
    • 11.1. Key Segment Analysis
    • 11.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Patient Demographics, 2021-2035
      • 11.2.1. Pediatric (< 12 years)
      • 11.2.2. Adolescent (12–17 years)
      • 11.2.3. Adult (18–64 years)
      • 11.2.4. Geriatric (≥ 65 years)
  • 12. Global Anti-Migraine Drugs Market Analysis, by End-users
    • 12.1. Key Segment Analysis
    • 12.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by End-users, 2021-2035
      • 12.2.1. Hospital & Inpatient Care
      • 12.2.2. Specialty Neurology & Headache Clinics
      • 12.2.3. Pain Management Clinics
      • 12.2.4. Ambulatory & Outpatient IV Infusion Centers
      • 12.2.5. Others
  • 13. Global Anti-Migraine Drugs Market Analysis and Forecasts, by Region
    • 13.1. Key Findings
    • 13.2. Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 13.2.1. North America
      • 13.2.2. Europe
      • 13.2.3. Asia Pacific
      • 13.2.4. Middle East
      • 13.2.5. Africa
      • 13.2.6. South America
  • 14. North America Anti-Migraine Drugs Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. North America Anti-Migraine Drugs Market Size- Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Drug Class
      • 14.3.2. Treatment Type
      • 14.3.3. Migraine Type
      • 14.3.4. Packaging Type
      • 14.3.5. Route of Administration
      • 14.3.6. Drug Type
      • 14.3.7. Patient Demographics
      • 14.3.8. End-users
      • 14.3.9. Country
        • 14.3.9.1. USA
        • 14.3.9.2. Canada
        • 14.3.9.3. Mexico
    • 14.4. USA Anti-Migraine Drugs Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Drug Class
      • 14.4.3. Treatment Type
      • 14.4.4. Migraine Type
      • 14.4.5. Packaging Type
      • 14.4.6. Route of Administration
      • 14.4.7. Drug Type
      • 14.4.8. Patient Demographics
      • 14.4.9. End-users
    • 14.5. Canada Anti-Migraine Drugs Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Drug Class
      • 14.5.3. Treatment Type
      • 14.5.4. Migraine Type
      • 14.5.5. Packaging Type
      • 14.5.6. Route of Administration
      • 14.5.7. Drug Type
      • 14.5.8. Patient Demographics
      • 14.5.9. End-users
    • 14.6. Mexico Anti-Migraine Drugs Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Drug Class
      • 14.6.3. Treatment Type
      • 14.6.4. Migraine Type
      • 14.6.5. Packaging Type
      • 14.6.6. Route of Administration
      • 14.6.7. Drug Type
      • 14.6.8. Patient Demographics
      • 14.6.9. End-users
  • 15. Europe Anti-Migraine Drugs Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Europe Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Drug Class
      • 15.3.2. Treatment Type
      • 15.3.3. Migraine Type
      • 15.3.4. Packaging Type
      • 15.3.5. Route of Administration
      • 15.3.6. Drug Type
      • 15.3.7. Patient Demographics
      • 15.3.8. End-users
      • 15.3.9. Country
        • 15.3.9.1. Germany
        • 15.3.9.2. United Kingdom
        • 15.3.9.3. France
        • 15.3.9.4. Italy
        • 15.3.9.5. Spain
        • 15.3.9.6. Netherlands
        • 15.3.9.7. Nordic Countries
        • 15.3.9.8. Poland
        • 15.3.9.9. Russia & CIS
        • 15.3.9.10. Rest of Europe
    • 15.4. Germany Anti-Migraine Drugs Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Drug Class
      • 15.4.3. Treatment Type
      • 15.4.4. Migraine Type
      • 15.4.5. Packaging Type
      • 15.4.6. Route of Administration
      • 15.4.7. Drug Type
      • 15.4.8. Patient Demographics
      • 15.4.9. End-users
    • 15.5. United Kingdom Anti-Migraine Drugs Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Drug Class
      • 15.5.3. Treatment Type
      • 15.5.4. Migraine Type
      • 15.5.5. Packaging Type
      • 15.5.6. Route of Administration
      • 15.5.7. Drug Type
      • 15.5.8. Patient Demographics
      • 15.5.9. End-users
    • 15.6. France Anti-Migraine Drugs Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Drug Class
      • 15.6.3. Treatment Type
      • 15.6.4. Migraine Type
      • 15.6.5. Packaging Type
      • 15.6.6. Route of Administration
      • 15.6.7. Drug Type
      • 15.6.8. Patient Demographics
      • 15.6.9. End-users
    • 15.7. Italy Anti-Migraine Drugs Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Drug Class
      • 15.7.3. Treatment Type
      • 15.7.4. Migraine Type
      • 15.7.5. Packaging Type
      • 15.7.6. Route of Administration
      • 15.7.7. Drug Type
      • 15.7.8. Patient Demographics
      • 15.7.9. End-users
    • 15.8. Spain Anti-Migraine Drugs Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Drug Class
      • 15.8.3. Treatment Type
      • 15.8.4. Migraine Type
      • 15.8.5. Packaging Type
      • 15.8.6. Route of Administration
      • 15.8.7. Drug Type
      • 15.8.8. Patient Demographics
      • 15.8.9. End-users
    • 15.9. Netherlands Anti-Migraine Drugs Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Drug Class
      • 15.9.3. Treatment Type
      • 15.9.4. Migraine Type
      • 15.9.5. Packaging Type
      • 15.9.6. Route of Administration
      • 15.9.7. Drug Type
      • 15.9.8. Patient Demographics
      • 15.9.9. End-users
    • 15.10. Nordic Countries Anti-Migraine Drugs Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Drug Class
      • 15.10.3. Treatment Type
      • 15.10.4. Migraine Type
      • 15.10.5. Packaging Type
      • 15.10.6. Route of Administration
      • 15.10.7. Drug Type
      • 15.10.8. Patient Demographics
      • 15.10.9. End-users
    • 15.11. Poland Anti-Migraine Drugs Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Drug Class
      • 15.11.3. Treatment Type
      • 15.11.4. Migraine Type
      • 15.11.5. Packaging Type
      • 15.11.6. Route of Administration
      • 15.11.7. Drug Type
      • 15.11.8. Patient Demographics
      • 15.11.9. End-users
    • 15.12. Russia & CIS Anti-Migraine Drugs Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Drug Class
      • 15.12.3. Treatment Type
      • 15.12.4. Migraine Type
      • 15.12.5. Packaging Type
      • 15.12.6. Route of Administration
      • 15.12.7. Drug Type
      • 15.12.8. Patient Demographics
      • 15.12.9. End-users
    • 15.13. Rest of Europe Anti-Migraine Drugs Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Drug Class
      • 15.13.3. Treatment Type
      • 15.13.4. Migraine Type
      • 15.13.5. Packaging Type
      • 15.13.6. Route of Administration
      • 15.13.7. Drug Type
      • 15.13.8. Patient Demographics
      • 15.13.9. End-users
  • 16. Asia Pacific Anti-Migraine Drugs Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Asia Pacific Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Drug Class
      • 16.3.2. Treatment Type
      • 16.3.3. Migraine Type
      • 16.3.4. Packaging Type
      • 16.3.5. Route of Administration
      • 16.3.6. Drug Type
      • 16.3.7. Patient Demographics
      • 16.3.8. End-users
      • 16.3.9. Country
        • 16.3.9.1. China
        • 16.3.9.2. India
        • 16.3.9.3. Japan
        • 16.3.9.4. South Korea
        • 16.3.9.5. Australia and New Zealand
        • 16.3.9.6. Indonesia
        • 16.3.9.7. Malaysia
        • 16.3.9.8. Thailand
        • 16.3.9.9. Vietnam
        • 16.3.9.10. Rest of Asia Pacific
    • 16.4. China Anti-Migraine Drugs Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Drug Class
      • 16.4.3. Treatment Type
      • 16.4.4. Migraine Type
      • 16.4.5. Packaging Type
      • 16.4.6. Route of Administration
      • 16.4.7. Drug Type
      • 16.4.8. Patient Demographics
      • 16.4.9. End-users
    • 16.5. India Anti-Migraine Drugs Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Drug Class
      • 16.5.3. Treatment Type
      • 16.5.4. Migraine Type
      • 16.5.5. Packaging Type
      • 16.5.6. Route of Administration
      • 16.5.7. Drug Type
      • 16.5.8. Patient Demographics
      • 16.5.9. End-users
    • 16.6. Japan Anti-Migraine Drugs Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Drug Class
      • 16.6.3. Treatment Type
      • 16.6.4. Migraine Type
      • 16.6.5. Packaging Type
      • 16.6.6. Route of Administration
      • 16.6.7. Drug Type
      • 16.6.8. Patient Demographics
      • 16.6.9. End-users
    • 16.7. South Korea Anti-Migraine Drugs Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Drug Class
      • 16.7.3. Treatment Type
      • 16.7.4. Migraine Type
      • 16.7.5. Packaging Type
      • 16.7.6. Route of Administration
      • 16.7.7. Drug Type
      • 16.7.8. Patient Demographics
      • 16.7.9. End-users
    • 16.8. Australia and New Zealand Anti-Migraine Drugs Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Drug Class
      • 16.8.3. Treatment Type
      • 16.8.4. Migraine Type
      • 16.8.5. Packaging Type
      • 16.8.6. Route of Administration
      • 16.8.7. Drug Type
      • 16.8.8. Patient Demographics
      • 16.8.9. End-users
    • 16.9. Indonesia Anti-Migraine Drugs Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Drug Class
      • 16.9.3. Treatment Type
      • 16.9.4. Migraine Type
      • 16.9.5. Packaging Type
      • 16.9.6. Route of Administration
      • 16.9.7. Drug Type
      • 16.9.8. Patient Demographics
      • 16.9.9. End-users
    • 16.10. Malaysia Anti-Migraine Drugs Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Drug Class
      • 16.10.3. Treatment Type
      • 16.10.4. Migraine Type
      • 16.10.5. Packaging Type
      • 16.10.6. Route of Administration
      • 16.10.7. Drug Type
      • 16.10.8. Patient Demographics
      • 16.10.9. End-users
    • 16.11. Thailand Anti-Migraine Drugs Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Drug Class
      • 16.11.3. Treatment Type
      • 16.11.4. Migraine Type
      • 16.11.5. Packaging Type
      • 16.11.6. Route of Administration
      • 16.11.7. Drug Type
      • 16.11.8. Patient Demographics
      • 16.11.9. End-users
    • 16.12. Vietnam Anti-Migraine Drugs Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Drug Class
      • 16.12.3. Treatment Type
      • 16.12.4. Migraine Type
      • 16.12.5. Packaging Type
      • 16.12.6. Route of Administration
      • 16.12.7. Drug Type
      • 16.12.8. Patient Demographics
      • 16.12.9. End-users
    • 16.13. Rest of Asia Pacific Anti-Migraine Drugs Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Drug Class
      • 16.13.3. Treatment Type
      • 16.13.4. Migraine Type
      • 16.13.5. Packaging Type
      • 16.13.6. Route of Administration
      • 16.13.7. Drug Type
      • 16.13.8. Patient Demographics
      • 16.13.9. End-users
  • 17. Middle East Anti-Migraine Drugs Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Middle East Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Product Type
      • 17.3.2. Drug Class
      • 17.3.3. Treatment Type
      • 17.3.4. Migraine Type
      • 17.3.5. Packaging Type
      • 17.3.6. Route of Administration
      • 17.3.7. Drug Type
      • 17.3.8. Patient Demographics
      • 17.3.9. End-users
      • 17.3.10. Country
        • 17.3.10.1. Turkey
        • 17.3.10.2. UAE
        • 17.3.10.3. Saudi Arabia
        • 17.3.10.4. Israel
        • 17.3.10.5. Rest of Middle East
    • 17.4. Turkey Anti-Migraine Drugs Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Drug Class
      • 17.4.3. Treatment Type
      • 17.4.4. Migraine Type
      • 17.4.5. Packaging Type
      • 17.4.6. Route of Administration
      • 17.4.7. Drug Type
      • 17.4.8. Patient Demographics
      • 17.4.9. End-users
    • 17.5. UAE Anti-Migraine Drugs Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Drug Class
      • 17.5.3. Treatment Type
      • 17.5.4. Migraine Type
      • 17.5.5. Packaging Type
      • 17.5.6. Route of Administration
      • 17.5.7. Drug Type
      • 17.5.8. Patient Demographics
      • 17.5.9. End-users
    • 17.6. Saudi Arabia Anti-Migraine Drugs Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Drug Class
      • 17.6.3. Treatment Type
      • 17.6.4. Migraine Type
      • 17.6.5. Packaging Type
      • 17.6.6. Route of Administration
      • 17.6.7. Drug Type
      • 17.6.8. Patient Demographics
      • 17.6.9. End-users
    • 17.7. Israel Anti-Migraine Drugs Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Drug Class
      • 17.7.3. Treatment Type
      • 17.7.4. Migraine Type
      • 17.7.5. Packaging Type
      • 17.7.6. Route of Administration
      • 17.7.7. Drug Type
      • 17.7.8. Patient Demographics
      • 17.7.9. End-users
    • 17.8. Rest of Middle East Anti-Migraine Drugs Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Drug Class
      • 17.8.3. Treatment Type
      • 17.8.4. Migraine Type
      • 17.8.5. Packaging Type
      • 17.8.6. Route of Administration
      • 17.8.7. Drug Type
      • 17.8.8. Patient Demographics
      • 17.8.9. End-users
  • 18. Africa Anti-Migraine Drugs Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Africa Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Drug Class
      • 18.3.2. Treatment Type
      • 18.3.3. Migraine Type
      • 18.3.4. Packaging Type
      • 18.3.5. Route of Administration
      • 18.3.6. Drug Type
      • 18.3.7. Patient Demographics
      • 18.3.8. End-users
      • 18.3.9. Country
        • 18.3.9.1. South Africa
        • 18.3.9.2. Egypt
        • 18.3.9.3. Nigeria
        • 18.3.9.4. Algeria
        • 18.3.9.5. Rest of Africa
    • 18.4. South Africa Anti-Migraine Drugs Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Drug Class
      • 18.4.3. Treatment Type
      • 18.4.4. Migraine Type
      • 18.4.5. Packaging Type
      • 18.4.6. Route of Administration
      • 18.4.7. Drug Type
      • 18.4.8. Patient Demographics
      • 18.4.9. End-users
    • 18.5. Egypt Anti-Migraine Drugs Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Drug Class
      • 18.5.3. Treatment Type
      • 18.5.4. Migraine Type
      • 18.5.5. Packaging Type
      • 18.5.6. Route of Administration
      • 18.5.7. Drug Type
      • 18.5.8. Patient Demographics
      • 18.5.9. End-users
    • 18.6. Nigeria Anti-Migraine Drugs Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Drug Class
      • 18.6.3. Treatment Type
      • 18.6.4. Migraine Type
      • 18.6.5. Packaging Type
      • 18.6.6. Route of Administration
      • 18.6.7. Drug Type
      • 18.6.8. Patient Demographics
      • 18.6.9. End-users
    • 18.7. Algeria Anti-Migraine Drugs Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Drug Class
      • 18.7.3. Treatment Type
      • 18.7.4. Migraine Type
      • 18.7.5. Packaging Type
      • 18.7.6. Route of Administration
      • 18.7.7. Drug Type
      • 18.7.8. Patient Demographics
      • 18.7.9. End-users
    • 18.8. Rest of Africa Anti-Migraine Drugs Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Drug Class
      • 18.8.3. Treatment Type
      • 18.8.4. Migraine Type
      • 18.8.5. Packaging Type
      • 18.8.6. Route of Administration
      • 18.8.7. Drug Type
      • 18.8.8. Patient Demographics
      • 18.8.9. End-users
  • 19. South America Anti-Migraine Drugs Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. South America Anti-Migraine Drugs Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Drug Class
      • 19.3.2. Treatment Type
      • 19.3.3. Migraine Type
      • 19.3.4. Packaging Type
      • 19.3.5. Route of Administration
      • 19.3.6. Drug Type
      • 19.3.7. Patient Demographics
      • 19.3.8. End-users
      • 19.3.9. Country
        • 19.3.9.1. Brazil
        • 19.3.9.2. Argentina
        • 19.3.9.3. Rest of South America
    • 19.4. Brazil Anti-Migraine Drugs Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Drug Class
      • 19.4.3. Treatment Type
      • 19.4.4. Migraine Type
      • 19.4.5. Packaging Type
      • 19.4.6. Route of Administration
      • 19.4.7. Drug Type
      • 19.4.8. Patient Demographics
      • 19.4.9. End-users
    • 19.5. Argentina Anti-Migraine Drugs Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Drug Class
      • 19.5.3. Treatment Type
      • 19.5.4. Migraine Type
      • 19.5.5. Packaging Type
      • 19.5.6. Route of Administration
      • 19.5.7. Drug Type
      • 19.5.8. Patient Demographics
      • 19.5.9. End-users
    • 19.6. Rest of South America Anti-Migraine Drugs Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Drug Class
      • 19.6.3. Treatment Type
      • 19.6.4. Migraine Type
      • 19.6.5. Packaging Type
      • 19.6.6. Route of Administration
      • 19.6.7. Drug Type
      • 19.6.8. Patient Demographics
      • 19.6.9. End-users
  • 20. KeyPlayers/ Company Profile
    • 20.1. AbbVie Inc.
      • 20.1.1. Company Details/ Overview
      • 20.1.2. Company Financials
      • 20.1.3. Key Customers and Competitors
      • 20.1.4. Business/ Industry Portfolio
      • 20.1.5. Product Portfolio/ Specification Details
      • 20.1.6. Pricing Data
      • 20.1.7. Strategic Overview
      • 20.1.8. Recent Developments
    • 20.2. Amgen Inc. (Aimovig)
    • 20.3. Cafergot (Advanz Pharma)
    • 20.4. Eli Lilly and Company
    • 20.5. GlaxoSmithKline plc
    • 20.6. Grünenthal Group (Zomig)
    • 20.7. H. Lundbeck A/S (Vyepti)
    • 20.8. Novartis AG
    • 20.9. Pfizer Inc. (Nurtec ODT)
    • 20.10. Teva Pharmaceutical Industries Ltd. (AJOVY)
    • 20.11. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation